Taking a new approach to tackle neurodegenerative diseases
Drug Discovery World
OCTOBER 4, 2022
Using its proprietary compound screening platform, Oligomerix discovers and develops differentiated, oral, small molecule inhibitors of tau self-association that are easy to administer and cost-effective. . Global dementia prevalence is expected to increase to 152 million in 2050, a 204% increase compared to 2018.
130 
Let's personalize your content